CompletedNot Applicable

MAAT For Young Adult Cancer Survivors

United States7 participantsStarted 2025-02-12

Plain-language summary

The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. Participants in this single-group pilot trial (N=9) will complete online self-report measures of cognitive symptoms, quality of life, treatment satisfaction and a brief online neuropsychological test battery at baseline and post-MAAT-YS timepoints.

Who can participate

Age range18 Years – 39 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged 18-39
✓. Diagnosed prior to 18 years of age with non-CNS solid tumor or leukemia/lymphoma without known CNS involvement
✓. At least 1 year after completion of treatment including chemotherapy, cancer-free
✓. English fluent
✓. Memory or other cognitive problems attributed to cancer and/or cancer treatment
✓. Score of \<10 on the FACT-Cog Impact on Quality of Life Scale
✓. Willing to use telehealth with internet access
✓. Willing to provide informed consent to participation

Exclusion criteria

✕. Severe non-cancer brain injury such as severe traumatic brain injury, stroke or toxic injury causing memory impairments;
✕. Currently meeting Diagnostic and Statistical Manual-5 (DSM-5) criteria for a severe psychiatric disorder, including substance abuse, mood, anxiety, or psychotic disorders, as assessed by the PRIME-MD;

What they're measuring

Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) v.3. Perceived Cognitive Impairments Scale (PCI)

Timeframe: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)

CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (1) Verbal Memory (VBM) (recognition memory for words)

Timeframe: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)

CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (2) Symbol Digit Coding (SDC) (visual motor processing speed)

Timeframe: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)

CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (3) Stroop Test (ST) (visual motor reaction time, processing speed and visual discrimination)

Timeframe: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)

CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (4) 4-Part Continuous Performance Test (FPCPT) (sustained attention and working memory)

Timeframe: Baseline to Post-Treatment (after 8 weekly telehealth MAAT visits)

Trial details

NCT IDNCT06150976

SponsorUniversity of Pittsburgh

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-05

View on ClinicalTrials.gov More Cancer trials

Plain-language summary

Who can participate

Age range18 Years – 39 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged 18-39
✓. Diagnosed prior to 18 years of age with non-CNS solid tumor or leukemia/lymphoma without known CNS involvement
✓. At least 1 year after completion of treatment including chemotherapy, cancer-free
✓. English fluent
✓. Memory or other cognitive problems attributed to cancer and/or cancer treatment
✓. Score of \<10 on the FACT-Cog Impact on Quality of Life Scale
✓. Willing to use telehealth with internet access
✓. Willing to provide informed consent to participation

Exclusion criteria

✕. Severe non-cancer brain injury such as severe traumatic brain injury, stroke or toxic injury causing memory impairments;
✕. Currently meeting Diagnostic and Statistical Manual-5 (DSM-5) criteria for a severe psychiatric disorder, including substance abuse, mood, anxiety, or psychotic disorders, as assessed by the PRIME-MD;